Investors looking for stocks that can make dramatic moves in short time frames recently got what they were looking for from Invivyd (NASDAQ: IVVD). Shares of the clinical-stage biotech stock more than doubled overnight after the company reported successful results from a late-stage clinical trial with an experimental COVID-19 prophylactic.

Is there more fuel in Invivyd's tank that can drive the stock higher?

On Dec. 18, Invivyd stock gained more than 150% after the company announced positive data from a phase 3 trial investigating VYD222 for the prevention of COVID-19. In the ongoing study, immunocompromised patients given an infusion of VYD222 produced high levels of serum virus-neutralizing antibodies (sVNA) against the omicron subvariant XBB.1.5.

Continue reading

Source Fool.com